MELANOTAN II

Mechanism of Action

Melanotan II is a cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide derived from pro-opiomelanocortin (POMC). It binds with high affinity to melanocortin receptors (MCRs), which are G protein-coupled receptors distributed throughout the skin, brain, and peripheral tissues.

1

Subcutaneous Administration

MT-II is administered subcutaneously. It is not orally bioavailable due to rapid proteolytic degradation in the GI tract.

2

Systemic Distribution

Following absorption, MT-II crosses the blood-brain barrier and distributes to melanocortin receptor-expressing tissues throughout the body.

3

MC1R Activation (Skin)

Binding to MC1R on melanocytes stimulates melanogenesis — the production of eumelanin (brown/black pigment). This produces the tanning effect without UV exposure.

4

MC3R / MC4R Activation (CNS)

Central melanocortin receptor activation suppresses appetite (MC4R hypothalamus) and activates pro-erectile pathways (MC3R/MC4R limbic system), producing the sexual and appetite effects.

5

Rapid Clearance

MT-II has a short plasma half-life (~30–60 minutes). Effects on melanin synthesis persist longer due to downstream signaling, but CNS effects are more transient.

Melanocortin Receptor Binding Profile

MT-II is non-selective — it binds all five melanocortin receptor subtypes. This broad activity is the source of both its research utility and its side effect profile.

Receptor

Primary Location

Effect of Activation

MT-II Affinity

MC1R

Melanocytes (skin, hair)

Melanin synthesis (tanning)

High

MC2R

Adrenal cortex

Cortisol release (ACTH receptor)

Low / non-selective

MC3R

Hypothalamus, limbic system

Energy homeostasis, sexual function

High

MC4R

Hypothalamus, brainstem

Appetite suppression, erectile function

High

MC5R

Exocrine glands, peripheral tissues

Sebaceous gland function

Moderate

Research History

1981

α-MSH identified as the endogenous melanocortin peptide responsible for skin pigmentation. University of Arizona researchers begin developing synthetic analogues.

1991

Melanotan I (afamelanotide) synthesized. First-generation α-MSH analogue with longer half-life.

1995

Melanotan II synthesized. More potent than MT-I with broader receptor activity including MC3R/MC4R. Accidental discovery of erectile effects in self-experimenting researcher (Dr. Hunter 'Mac' Hadley).

1998

First published human trial of MT-II for erectile dysfunction. Wessells et al., Journal of Urology. Demonstrated efficacy but high nausea incidence.

2000s

PT-141 (bremelanotide) developed as a more selective analogue targeting sexual dysfunction without the broad tanning effect. Enters clinical trials.

2007

FDA issues warning letters to distributors of MT-II sold as 'research chemicals.' Cites illegal marketing for human use without approval.

2019

Bremelanotide (Vyleesi) receives FDA approval for HSDD in premenopausal women — the first FDA-approved melanocortin-based drug.

2020s

MT-II remains widely available through research chemical suppliers. Continues to be studied in preclinical models for melanoma prevention, obesity, and sexual dysfunction.

Melanotan II vs. Bremelanotide (PT-141)

These are related but distinct compounds. Bremelanotide was developed specifically to improve on MT-II's selectivity and safety profile for sexual dysfunction applications.

Aspect

Melanotan II

Bremelanotide (PT-141)

Full name

Melanotan II

Bremelanotide (PT-141)

Structure

Cyclic heptapeptide analogue of α-MSH

Metabolite of Melanotan II; linear hexapeptide

FDA status

Not approved — FDA warning letters issued

FDA-approved (Vyleesi, 2019)

Approved indication

None

HSDD in premenopausal women

Primary research use

Tanning, sexual dysfunction, appetite suppression

Female sexual dysfunction (FDA-approved)

Melanocortin selectivity

Non-selective (MC1R, MC3R, MC4R, MC5R)

More selective for MC3R/MC4R

Tanning effect

Strong (MC1R agonism)

Minimal (reduced MC1R activity)

Route

Subcutaneous injection

Subcutaneous autoinjector (Vyleesi)

Half-life

~30–60 min

~2.7 hours

Nausea incidence

High (~80% in trials)

~40% (dose-dependent)

Side Effects & Safety Profile

The following adverse effects were documented in clinical trial data and case reports. The broad receptor non-selectivity of MT-II is the primary driver of its side effect burden compared to more selective analogues.

Nausea / vomiting

Moderate

Frequency: Very common (>50%)

Most common adverse effect in clinical trials. Dose-dependent. Often occurs within 1–2 hours of administration.

Facial flushing

Mild

Frequency: Very common (>50%)

Vasodilation effect. Typically transient (30–60 min).

Spontaneous erections

Mild–Moderate

Frequency: Common (males)

MC4R-mediated. Can be prolonged (priapism risk at high doses).

Increased mole/nevus darkening

Moderate (monitoring required)

Frequency: Common

MC1R activation can darken existing melanocytic nevi. Requires dermatological monitoring. Potential melanoma risk signal.

Hyperpigmentation

Mild–Moderate

Frequency: Common

Diffuse skin darkening beyond intended tanning effect. Can be uneven.

Appetite suppression

Mild

Frequency: Common

MC4R-mediated hypothalamic effect. Can cause unintended weight loss.

Fatigue / lethargy

Mild

Frequency: Uncommon

Reported in some trial subjects. Mechanism unclear.

Hypertension

Moderate

Frequency: Uncommon

Transient blood pressure elevation reported. Cardiovascular monitoring recommended.

Melanoma (theoretical risk)

Serious (theoretical)

Frequency: Unknown

MC1R activation promotes melanogenesis. Theoretical concern for melanoma promotion in susceptible individuals. No definitive causal data in humans.

Regulatory Status by Jurisdiction

🇺🇸United States (FDA)Not approved

FDA has issued warning letters to distributors. Not approved for any indication. Legal for laboratory research use only.

🇬🇧United Kingdom (MHRA)Not approved — warnings issued

MHRA has issued multiple warnings about 'Barbie jab' products. Classified as a prescription-only medicine if sold for human use.

🇦🇺Australia (TGA)Schedule 4 (prescription only)

Listed as a Schedule 4 prescription-only medicine. Illegal to import or supply without a prescription.

🇪🇺European Union (EMA)Not approved

No marketing authorization in any EU member state. Subject to national regulations.

🏅WADAProhibited (S4 — Hormone modulators)

Listed under S4 Hormone and Metabolic Modulators. Prohibited in-competition and out-of-competition for all athletes.

🔬Research Use (US)Legal for research

Legal to purchase and use for legitimate laboratory research. Must be labeled 'for research use only.' Not for human administration.

Related Research Guides

MT-2 Compound Profile

Amino acid sequence, molecular weight, storage, and reconstitution

PT-141 Compound Profile

Bremelanotide — the FDA-approved melanocortin analogue

Peptide Calculator

Reconstitution & draw volume calculator for MT-2 and 26 other compounds

Are Peptides FDA-Approved?

Which peptides have FDA approval and what the 2023 guidance changed

Peptide Side Effects

Adverse effects by body system across all major compound classes

Are Peptides Legal?

Jurisdiction-by-jurisdiction legal status including WADA

Frequently Asked Questions

What is Melanotan II?

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is a non-selective melanocortin receptor agonist that activates MC1R (producing skin tanning), MC3R and MC4R (producing appetite suppression and sexual effects), and MC5R. It was developed at the University of Arizona in the 1990s as part of research into skin pigmentation and photoprotection.

Is Melanotan II FDA-approved?

No. Melanotan II is not FDA-approved for any indication. The FDA has issued warning letters to distributors selling MT-II for human use. It is sold legally for laboratory research purposes only. Bremelanotide (Vyleesi), a related but distinct melanocortin analogue, received FDA approval in 2019 for hypoactive sexual desire disorder — but it is a different compound with different receptor selectivity and pharmacokinetics.

What is the difference between Melanotan II and PT-141?

PT-141 (bremelanotide) is a metabolite of Melanotan II and a related but distinct compound. It has greater selectivity for MC3R and MC4R (sexual function) and reduced activity at MC1R (tanning). PT-141 was developed specifically to isolate the sexual dysfunction effects while minimizing the tanning and nausea side effects of MT-II. PT-141 received FDA approval as Vyleesi in 2019; MT-II has not.

What are the main side effects of Melanotan II?

The most common adverse effect in clinical trials is nausea, occurring in over 50% of subjects. Other common effects include facial flushing, spontaneous erections in males, darkening of existing moles (melanocytic nevi), and diffuse hyperpigmentation. Theoretical concerns include melanoma risk due to MC1R activation, though no definitive causal data exists in humans. The FDA warning letters cite concerns about these safety risks in the context of unregulated human use.

What is Melanotan II used for in research?

Research applications of MT-II include: melanocortin receptor pharmacology (characterizing MC1R–MC5R binding and signaling), photoprotection research (whether pre-tanning reduces UV-induced DNA damage), obesity and appetite regulation (MC4R-mediated satiety signaling), sexual dysfunction models (MC3R/MC4R pro-erectile pathways), and melanoma biology (the role of MC1R in melanogenesis and malignant transformation).

Is Melanotan II the same as the 'Barbie drug'?

Yes — Melanotan II is commonly referred to as the 'Barbie drug' or 'Barbie jab' in media coverage, particularly in the UK and Australia, where it has been widely used for cosmetic tanning. The nickname refers to its use for achieving a tanned appearance. Both the FDA (US) and the MHRA (UK) have issued warnings about its unregulated use due to safety concerns including nausea, mole changes, and unknown long-term risks.